I have to respectfully disagree with you that "even" higher margins can be obtained. The key strategic advantage of CTDH is it's ability to manufacture custom bulk cyclodextrin derivatives for lower prices than otherwise possible through traditional methods.
Profit margins on the NSP side will and should go down as volume overall sales increase as opposed to the fine chemical CTD division. Believe I am not saying anything contrary to what has been publicly reported and even reiterated by Dr. Tate in his videos.
The sales & marketing team was mentioned not one year but I believe already three years ago (i.e. ...interviewing strong candidates).
Be nice but really am not waiting for a "medicine" to come out of any of it even though it be nice but is just a long shot. If (when?) it happens would be frosting on the cake but at least I have invested because of their potential ability to tap into "bulk" wholesale market demand (i.e. NSP).
NSP, not the medical rocketship dream, is what will drive this puppy at least in the short/mid term.
Having said that what I am waiting for are some real indications of an increasing NSP contribution to the bottom line with "new" customers.
Market Data 
Markets 
AI
